COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs

Ann Rheum Dis. 2021 Feb;80(2):e14. doi: 10.1136/annrheumdis-2020-217681. Epub 2020 May 15.

Authors

Affiliations

¹ Department of Medicine, Surgery and Neurosciences, Rheumatology Unit, University of Siena, Siena, Italy [email protected].
² Department of Medicine, Surgery and Neurosciences, Pneumology Unit, University of Siena, Siena, Italy.
³ Department of Medicine, Surgery and Neurosciences, Rheumatology Unit, University of Siena, Siena, Italy.

PMID: 32414804
DOI: 10.1136/annrheumdis-2020-217681

No abstract available

Keywords: antirheumatic agents; autoimmune diseases; sarcoidosis.

Publication types

Letter
Comment

MeSH terms

Antirheumatic Agents* / adverse effects
COVID-19*
Humans
Rheumatic Diseases* / drug therapy
SARS-CoV-2
Synthetic Drugs* / therapeutic use

Substances

Antirheumatic Agents
Synthetic Drugs